Karavolias, Ioannis;
Karampinos, Konstantinos I;
Kani, Eleni-Rafaela;
Drougkas, Konstantinos;
Karampinou, Vasiliki Kleopatra;
Karavolia, Despoina Maria;
Koumprentziotis, Ioannis-Alexios;
... Gousias, Konstantinos; + view all
(2025)
Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.
BMC Cancer
, 25
, Article 1027. 10.1186/s12885-025-14397-1.
(In press).
Preview |
Text
Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients a meta-analysis.pdf - Published Version Download (4MB) | Preview |
Abstract
BACKGROUND: Glioblastoma (GB) is the most common and fatal primary central nervous system malignancy in adults. Various immunotherapies, including vaccination, are under investigation for their potential to extend survival in GB patients. Vaccination therapy has shown variable but promising outcomes across studies. This meta-analysis aims to evaluate the efficacy of available vaccines for newly diagnosed and recurrent GB. / / METHODS: We conducted a systematic search in PubMed, Scopus, and Web of Science to identify randomized or non-randomized double-arm studies involving adult GB patients treated with vaccines. Overall survival (OS) and progression-free survival (PFS) were the primary outcomes, with effect sizes represented as hazard ratios (HR) and calculated using a random-effects model. Funnel plots, Egger’s and Begg-Mazumdar tests assessed publication bias, and the chi-square (Q) statistic, I² statistic, and tau-squared (T²) parameter addressed heterogeneity. / / RESULTS: A total of 2,792 patients from 23 clinical studies were included. Our findings showed significant improvements in PFS (HR, 0.64; p < 0.001) and OS (HR, 1.09; p < 0.00001) with minimal publication bias but notable heterogeneity. Meta-regression identified vaccine type and publication year as influential factors. Subgroup analysis demonstrated survival benefits with dendritic cell and viral vector vaccines, with a trend towards lower 6-methylguanine-DNA methyltransferase (MGMT) methylation rates. Sensitivity analysis confirmed the robustness of our results. / / CONCLUSIONS: Vaccination therapy showed potential survival benefits for GB patients; however, further phase III studies are needed to validate these results, elucidate biological mechanisms, and strive for improved trial designs and patient stratification.
| Type: | Article |
|---|---|
| Title: | Efficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1186/s12885-025-14397-1 |
| Publisher version: | https://doi.org/10.1186/s12885-025-14397-1 |
| Language: | English |
| Additional information: | © The Author(s), 2025. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Keywords: | Cancer vaccines, Glioblastoma, Brain cancer. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10211881 |
Archive Staff Only
 |
View Item |
